OncoTherapy Science, Inc. (TSE:4564) announced that it will issue 350,000 31st stock acquisition rights at a price of ¥35 per stock acquisition rights for gross proceeds of ¥12,250,000 on April 12, 2021. The transaction will include participation from Daiwa Securities Co., Ltd., Investment Arm. Each stock acquisition right is convertible into 100 shares. The stock acquisition right will be convertible into a total of 35,000,000 potential shares of the company. The initial exercise price of the stock acquisition right will be ¥123, minimum exercise price will be ¥74 and has no maximum exercise price. The transaction will take place through third party allotment. The company will pay attorney's fees, stock acquisition rights evaluation costs, and other administrative costs such as securities registration statement, document preparation fee and change registration fee. The stock acquisition rights can be exercised from April 30, 2021 to May 1, 2023. The transaction is expected to close on April 28, 2021. The transaction was approved by the board of directors of the company.